GSK, Angiochem to develop drugs for lysosomal disease symptoms

02/27/2012 | Reuters

GlaxoSmithKline and Angiochem agreed to develop treatments intended to relieve neurological symptoms related to lysosomal storage diseases. Angiochem could get more than $300 million, including as much as $31.5 million upfront, plus sales royalties.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Director, Payer Marketing
Avalere Health
Washington, DC
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX